1
项与 LD PepGNP-SARSCoV2(Emergex Vaccines Holding) 相关的临床试验A Phase-I, Double-blind, Randomized, Vehicle-controlled, Dose-finding, Safety Study of a Synthetic Nanoparticle-based, T Cell Priming Peptide Vaccine Against SARS-CoV-2 in Healthy Adults in Switzerland
This trial is Stage 2 of a 2-part adaptive trial. The study aims to investigate the safety of 2 doses of a T-cell priming specific cocktail of Coronaviruses peptides mounted on a gold nanoparticle.
Note: Stage 1 of the 2-part adaptive trial, testing a specifically selected mix of Dengue virus peptides, commenced Aug 2021. This is now in follow up (NCT04935801).
100 项与 LD PepGNP-SARSCoV2(Emergex Vaccines Holding) 相关的临床结果
100 项与 LD PepGNP-SARSCoV2(Emergex Vaccines Holding) 相关的转化医学
100 项与 LD PepGNP-SARSCoV2(Emergex Vaccines Holding) 相关的专利(医药)
100 项与 LD PepGNP-SARSCoV2(Emergex Vaccines Holding) 相关的药物交易